



(51) International Patent Classification:

C07K 14/575 (2006.01) **C07K 14/47** (2006.01)
A61P 9/00 (2006.01) **C12N 15/07** (2006.01)
A61P 9/04 (2006.01) **C12N 15/62** (2006.01)
A61P 9/10 (2006.01) **C07K 16/26** (2006.01)
A61P 9/12 (2006.01) **C12N 15/16** (2006.01)
A61P 9/14 (2006.01) **G01N 33/53** (2006.01)
A61P 15/10 (2006.01) **G01N 33/563** (2006.01)
A61P 31/18 (2006.01)

(21) International Application Number:

PCT/SG2014/000574

(22) International Filing Date:

3 December 2014 (03.12.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/911,276 3 December 2013 (03.12.2013) US
 14/496,600 25 September 2014 (25.09.2014) US

(71) Applicant: **AGENCY FOR SCIENCE, TECHNOLOGY
AND RESEARCH** [SG/SG]; 1 Fusionopolis Way, #20-10
Connexis, Singapore 138632 (SG).

(72) Inventor: **REVERSADE, Bruno**; c/o Institute of Medical
Biology, 8A Biomedical Grove, #06-06 Immunos, Singa-
pore 138648 (SG).

(74) Agent: **KHOO, Chong Yee**; Cantab LLP, VBox 881846,
Singapore 919191 (SG).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,

[Continued on next page]

(54) Title: POLYPEPTIDES, NUCLEIC ACIDS AND USES THEREOF

FIGURE 1A



(57) Abstract: We describe an ELABELA polypeptide comprising a sequence CXXXRCXXXHSRVPFP (SEQ ID NO: 1), in which X signifies an amino acid residue, such as a sequence selected from the group consisting of: SEQ ID NO: 2 to SEQ ID NO: 18, preferably CLQRRCMPLHSRVPFP (SEQ ID NO: 2), or a fragment, homologue, variant or derivative thereof, which polypeptide is capable of maintaining self-renewal and/or pluripotency of a stem cell.



LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, **Published:**

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*